EMPA-REG - the "diuretic hypothesis"

J Diabetes Complications. 2016 Jan-Feb;30(1):3-4. doi: 10.1016/j.jdiacomp.2015.10.012. Epub 2015 Oct 21.

Author

John McMurray¹

Affiliation

¹ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland. Electronic address: John.McMurray@glasgow.ac.uk.

PMID: 26597600
DOI: 10.1016/j.jdiacomp.2015.10.012

No abstract available

Publication types

Editorial

MeSH terms

Anti-Arrhythmia Agents / therapeutic use
Arrhythmias, Cardiac / complications
Arrhythmias, Cardiac / epidemiology
Arrhythmias, Cardiac / prevention & control
Arrhythmias, Cardiac / therapy
Benzhydryl Compounds / therapeutic use*
Controlled Clinical Trials as Topic
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / metabolism
Diabetic Cardiomyopathies / epidemiology
Diabetic Cardiomyopathies / prevention & control*
Diabetic Cardiomyopathies / therapy
Diuretics / therapeutic use*
Glucosides / therapeutic use*
Heart Failure / complications
Heart Failure / epidemiology
Heart Failure / prevention & control*
Heart Failure / therapy
Hospitalization
Humans
Hypoglycemic Agents / therapeutic use*
Membrane Transport Modulators / therapeutic use
Models, Biological*
Risk
Sodium-Glucose Transporter 2 / metabolism
Sodium-Glucose Transporter 2 Inhibitors

Substances

Anti-Arrhythmia Agents
Benzhydryl Compounds
Diuretics
Glucosides
Hypoglycemic Agents
Membrane Transport Modulators
SLC5A2 protein, human
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin